ArriVent's lung cancer treatment fails late-stage trial
AVBP•ArriVent BioPharma said its therapy for patients with a type of lung cancer did not meet the main goal in a late-stage trial.
1. Trial results
ArriVent BioPharma said its therapy for patients with a type of lung cancer did not meet the main goal in a late-stage trial.
